EZH2 and myelodysplastic syndrome: In myelodysplastic syndromes and in clonal hematopoiesis (CHIP), EZH2 and TET2 have been reported to be associated with higher rate of cardio-vascular events (20), and TET2 mutations (at low allelic burden) seem to positively predict the response to azacitidine (21).